CHOROIDAL NEOVASCULARIZATION
Clinical trials for CHOROIDAL NEOVASCULARIZATION explained in plain language.
Never miss a new study
Get alerted when new CHOROIDAL NEOVASCULARIZATION trials appear
Sign up with your email to follow new studies for CHOROIDAL NEOVASCULARIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for wet AMD: experimental drug tiespectus faces off against standard treatment
Disease control Recruiting nowThis study tests a new medicine called tiespectus (also known as MK-8748 or EYE201) for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 960 people with untreated wet AMD will receive either tiespectus or the standard treatment aflibercept via eye…
Matched conditions: CHOROIDAL NEOVASCULARIZATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 25, 2026 09:26 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 960 adults with untreated wet AMD will receive eye injections and be followed for a year to see if…
Matched conditions: CHOROIDAL NEOVASCULARIZATION
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC